CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...
We transfer coverage of CSL, a global leader in plasma therapies, influenza vaccinations, and iron and kidney products. Shares have plummeted over 60% in the last two years on several earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results